Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 15/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.53 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4786332 | 0.95 | HCRTR1 (0.51) | HCRTR1HCRTR2NR1I3 | |
| SCHEMBL1398768 | 0.94 | HCRTR1 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL1398798 | 0.92 | HCRTR1 (0.53) | HCRTR1HCRTR2 | |
| SCHEMBL1398771 | 0.91 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL1398725 | 0.91 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL1398806 | 0.90 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL1398822 | 0.88 | HCRTR1 (0.67) | HCRTR1HCRTR2 | |
| SCHEMBL1398650 | 0.87 | HCRTR1 (0.67) | HCRTR1HCRTR2 | |
| SCHEMBL1398879 | 0.87 | HCRTR1 (0.67) | HCRTR1HCRTR2 | |
| SCHEMBL1398568 | 0.87 | HCRTR1 (0.67) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994336-B2 | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885NR1I3 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.